





PROXY FORM FOR ANNUAL GENERAL MEETING



Event Code:



I/We the undersigned am/are a controlling shareholder and/or have a personal interest<sup>1</sup> in the adoption of Resolution 10:

yes  no

I/We the undersigned, being (a) shareholder(s) of the above Company hereby appoint the Chair of the meeting as my/our proxy or the following person



as my/our proxy to attend, speak and vote for me/us and on my/our behalf as directed below at the Annual General Meeting of the Company to be held on Tuesday, 5 May 2026 at 09:00 a.m. (UK time) and at any adjournment thereof

<sup>1</sup> As such terms are defined in Note 19 to the Annual General Meeting Notice.

THE RESOLUTIONS

Please mark 'X' to indicate how you wish to vote

As ordinary business to consider, and, if thought fit, pass Resolutions 1 to 6 inclusive below:

- 1. To re-elect David Zruia, who stands for re-election pursuant to Article 42 of the Company's Articles of Association, as a Director. For  Against  Vote Withheld
- 2. To re-elect Elad Even-Chen, who stands for re-election pursuant to Article 42 of the Company's Articles of Association, as a Director. For  Against  Vote Withheld
- 3. To re-elect Steve Baldwin, who stands for re-election pursuant to Article 42 of the Company's Articles of Association, as an Independent Non-Executive Director. For  Against  Vote Withheld
- 4. To re-elect Prof. Varda Liberman, who stands for re-election pursuant to Article 42 of the Company's Articles of Association, as an Independent Non-Executive Director. For  Against  Vote Withheld
- 5. To re-elect Prof. Jacob A. Frenkel, who stands for re-election pursuant to Article 42 of the Company's Articles of Association, as an Independent Non-Executive Director (if re-elected, Prof. Jacob A. Frenkel shall continue to serve as Chair of the Company's Board of Directors following the Annual General Meeting). For  Against  Vote Withheld
- 6. To re-appoint Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company's independent external auditor for the period ending at the close of the Company's next annual general meeting of shareholders, and to authorise the Company's Board of Directors (with power of delegation to its audit committee) to fix the remuneration to be paid to such auditors. For  Against  Vote Withheld

As special business to consider, and, if thought fit, pass Resolutions 7 to 11 inclusive below:

- 7. To authorise the Directors pursuant to Article 10(c) of the Company's Articles of Association to allot and issue up to 3,497,545 ordinary shares (representing approximately 5 per cent of the Company's issued share capital (excluding shares held in treasury) as at 18 March 2026) for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Article 10(b) of the Articles of Association did not apply to such allotment. For  Against  Vote Withheld
- 8. To authorise the Directors pursuant to Article 10(c) of the Company's Articles of Association to allot and issue up to 3,497,545 ordinary shares (representing approximately 5 per cent of the Company's issued share capital (excluding shares held in treasury) as at 18 March 2026) for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Article 10(b) of the Articles of Association did not apply to such allotment and issue, such authority to be limited to the allotment of equity securities or sale of treasury shares, to be used only for the purposes of financing (or refinancing, if the authority is to be used within twelve months after the original transaction) a transaction which the Board determines to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of the Annual General Meeting Notice. For  Against  Vote Withheld
- 9. To authorise the Company to make purchases of up to 6,995,090 ordinary shares (representing approximately 10 per cent of the Company's issued share capital (excluding shares held in treasury) as at 18 March 2026) for cash. For  Against  Vote Withheld
- 10. As required by the Israeli Companies Law, 5759-1999 ("Companies Law"), to approve a one-year extension to the Company's current Remuneration Policy for Directors and Executives (FY 2024 - FY 2026), commencing on 1 January 2027, with the Remuneration Policy's terms remaining identical to the terms of the Company's current Remuneration Policy (FY 2024 - FY 2026). For  Against  Vote Withheld
- 11. As an advisory vote, to approve the 2025 Directors' Remuneration Report, in the form set out on pages 92 to 103 of the Company's Annual Report for the financial year ended 31 December 2025. For  Against  Vote Withheld

Signature

Date

## Notes to your Proxy Form

1. If you require additional forms, please contact MUFG Corporate Markets: via email at [shareholderenquiries@cm.mpms.mufg.com](mailto:shareholderenquiries@cm.mpms.mufg.com) or at +44 (0) 371 664 0391. All forms must be signed and should be returned together in the same envelope. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Telephone hours are between 9.00 a.m. – 5.30 p.m. (UK time), Monday to Friday excluding public holidays in England and Wales. Alternatively, you may photocopy this form.
2. To be valid, any Form of Proxy or other instrument appointing a proxy and any power of attorney or other authority under which it is signed, or a notarially certified or office copy of such power or authority, must be received by post or (during normal business hours only) by hand at (i) MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL or (ii) Plus500, Investor Relations, Matam, Building 10.2, Haifa 3115001, Israel (or by email to [ir@plus500.com](mailto:ir@plus500.com)), by no later than 09.00 a.m. (UK time) on 30 April 2026.
3. The return of a completed Form of Proxy will not prevent a shareholder from attending, asking questions or voting at the Annual General Meeting.
4. Please indicate how you wish your votes to be cast by placing "X" in the box provided. On receipt of this form duly signed, you will be deemed to have authorised your proxy to vote, or to abstain from voting, as per your instructions. If no voting instruction is indicated, your proxy will vote or abstain from voting on the specified resolution at their discretion.
5. The 'Vote Withheld' option is provided to enable you to abstain from voting on the resolutions. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
6. Pursuant to the Companies Law, 5759-1999 (the "Companies Law"), to be entitled to attend and to vote at the Annual General Meeting (and for the purpose of the determination by the Company of the votes they may cast), shareholders must be registered in the register of the Company at close of business on 31 March 2026. Changes to the Company's register after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the Annual General Meeting.
7. Any shareholder attending the Annual General Meeting is entitled pursuant to the Companies Law to ask any question before (by emailing [ir@plus500.com](mailto:ir@plus500.com)), or during the meeting, to the business being dealt with at the meeting. The Company will answer any such questions unless: (i) to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information; or (ii) the answer has already been given on a website in the form of any answer to a question; or (iii) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.
8. As at 18 March 2026 (being the last practicable date prior to any publication of the Annual General Meeting Notice), the Company's issued share capital consisted of 114,888,377 ordinary shares carrying one vote each (including 44,937,473 ordinary shares held by the Company in treasury which do not carry any voting rights). The total voting rights in the Company as at 18 March 2026 were, therefore, 69,950,904.
9. The Board recommends that shareholders vote in favour of all items in the Annual General Meeting Notice.



**Please return using addressed envelope supplied**